Covid-19 roundup: FDA grants priority review to Roche's Actemra; WHO suspends UN supply of Covaxin — report
After more than 9 months after the WHO gave the all-clear on IL-6 drugs for use in patients with Covid-19, including Roche’s immunosuppressant and rheumatoid arthritis drug Actemra, the drug is now before the FDA for an official review.
Roche announced this morning that the FDA had accepted the pharma’s sBLA for Actemra, which had already been used in other parts of the world for hospitalized patients with Covid-19. The drug had already won an EUA from the FDA back in June, just a few weeks before the WHO gave its thumbs-up to the IL-6 drug class, which also includes Sanofi’s Kevzara.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
